Related Experiment Video
Updated: Jun 15, 2026
05:14
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
Published on: September 8, 2021
[Adherence to therapy in multiple sclerosis and schizophrenia].
1Bayer Schering Pharma/Bayer Vital GmbH, Medizin, Neurologie/Immunologie/Ophthalmologie, 51368 Leverkusen. patrick.bussfeld@bayerhealthcare.com
Fortschritte Der Neurologie-Psychiatrie
|March 10, 2010
Summary
Patient adherence to medical advice is crucial but often low in schizophrenia and multiple sclerosis (MS). Improving adherence requires further research and evidence-based interventions for these neurological and psychiatric conditions.
Area of Science:
- Neurology
- Psychiatry
- Health Services Research
Background:
- Adherence, defined as patient behavior aligning with healthcare recommendations, is critical for treatment efficacy.
- Factors influencing adherence are under-examined in neurological and psychiatric diseases.
- Inconsistent definitions and study periods lead to variable adherence rate data.
Purpose of the Study:
- To review and synthesize current understanding of adherence in schizophrenia and multiple sclerosis (MS).
- To identify existing and potential strategies for improving adherence in these patient populations.
- To highlight the need for further research and scientific evaluation of adherence interventions.
Main Methods:
- Review of existing literature on patient adherence in schizophrenia and MS.
- Analysis of reported adherence rates and influencing factors.
- Evaluation of current and proposed interventions for adherence improvement.
Main Results:
- Estimated adherence rates are approximately 50% for schizophrenia and 50-60% for MS.
- Interventions like psychoeducational programs and antipsychotic depot formulations show limited evidence in schizophrenia.
- MS nurse services are recognized for MS, but further research is needed to optimize adherence support.
Conclusions:
- Adherence rates in both schizophrenia and MS are notably low.
- There is a significant need for developing and scientifically evaluating new measures to enhance patient adherence in these conditions.
- Optimizing adherence interventions is essential for improving patient outcomes in neurological and psychiatric care.
Related Concept Videos
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:29Psychological and Sociocultural Causes of Schizophrenia
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:17Schizophrenia
Schizophrenia, a term introduced by Swiss psychiatrist Eugen Bleuler in 1911, describes a severe psychological disorder marked by profound disruptions in attention, thought processes, language, emotion, and interpersonal relationships. The core feature of schizophrenia is psychosis — a state characterized by a fundamental detachment from reality. This disconnection manifests through distorted logic, impaired perception, and atypical behavior, severely affecting the lives of those diagnosed.